Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: Full results after extended follow-up of the Phase 2 CheckMate 205 trial Meeting Abstract
| Authors: | Fanale, M.; Engert, A.; Younes, A.; Armand, P.; Ansell, S.; Zinzani, P. L.; Timmerman, J. M.; Collins, G. P.; Ramchandren, R.; Cohen, J. B.; De Boer, J. P.; Kuruvilla, J.; Savage, K. J.; Trneny, M.; Rodig, S.; Shipp, M.; Kato, K.; Sumbul, A.; Farsaci, B.; Santoro, A. |
| Abstract Title: | Nivolumab for relapsed/refractory classical Hodgkin lymphoma after autologous transplant: Full results after extended follow-up of the Phase 2 CheckMate 205 trial |
| Meeting Title: | 14th International Conference on Malignant Lymphoma |
| Journal Title: | Hematological Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2017 Jun 14-17 |
| Meeting Location: | Lugano, Switzerland |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2017-06-07 |
| Start Page: | 135 |
| End Page: | 136 |
| Language: | English |
| ACCESSION: | 123459851 |
| DOI: | 10.1002/hon.2437_124 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cin20 |
| DOI/URL: | |
| Notes: | Meeting Abstract: 125 -- Accession Number: 123459851 -- Entry Date: In Process -- Revision Date: 20170608 -- Publication Type: Article -- Supplement Title: Jun2017 Supplement -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: cin20 |
